News | February 21, 2024
AstraZeneca completes acquisition of Icosavax
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
Launches collaborative centre for translational research in head and neck cancer
The 200 bedded hospital owned & operated by Alexis
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Subscribe To Our Newsletter & Stay Updated
